Consortia Health Secures $2 Million in New Financing to Support Continued Growth

Personalized Pelvic Wellness Health Care Company Expands Commercial Activities

AUSTIN, TX - April 13, 2017 Consortia Health Holdings, Inc, a Personalized Pelvic Wellness health care company that provides clinically-relevant individualized diagnosis, therapy and education to help physicians treat their patients with incontinence, pelvic pain, sexual dysfunction and other pelvic disorders, today announced that it has closed a $2 million preferred round of financing. The round was led by Ponil Ventures, a current investor, and included Golden Seeds and Belle Michigan as new investors. The new financing will fund the growth needed to assist Consortia Health as they continue building the leading Pelvic Wellness Company.

"We are delighted to announce this infusion of capital. Together with our investors, this round will help support the rapid growth of Consortia Health," said Gail S Page, Cofounder and Chair of the Board. "Our mission is to help clinicians improve the treatment outcomes of patients. We are committed to being the leader in Pelvic Wellness and will continue adding proven therapy and education to enhance our current services."

Urinary Incontinence is an underdiagnosed and underreported problem that increases with age. According to the National Association for Continence, an estimated 200 million people suffer from this condition worldwide. Childbirth is a leading cause for women and incontinence is reported to be the second leading reason for admission to a nursing home for the elderly. The effects of these disorders range from daily living disruptions to incapacitating people in their personal, social and occupational everyday lives. According to published studies, the economic burden, due to pelvic floor disorders, to the US healthcare system is estimated to surpass $80 billion per year in 2020.

"Our combination of healthcare knowledge and partnership with the physicians allows us to offer the latest technological advances to patients in a clinical, medical, and private environment, which we believe will encourage those suffering to seek treatment and allow them to be in control of their lives. Consortia's ProPelvic solutions are medically driven and offer clinicians an integrated delivery method of treatment to serve their patients. Published peer review studies report an 80- 90% improvement of symptoms," stated Mary Lake Polan, MD, PhD,MPH Clinical Professor in Obstetrics, Gynecology, and Reproductive Sciences, Yale University and Chair of the Consortia Health Clinical/Medical Advisory Board.